Browse the evidence

Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (-10%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly semaglutide injections, combined with diet and exercise, can lead to significant weight loss (around 10%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.

Weekly subcutaneous liraglutide (3.0 mg) produces significant weight loss (-5.24 kg) and improves cardiometabolic markers in adults with overweight/obesity, though it is less effective than semaglutide 2.4 mg.

If you have obesity or overweight with related health issues, daily liraglutide injections, combined with diet and exercise, can lead to moderate weight loss (around 5 kg) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated. Note that it may be less effective than other options like semaglutide.

Novel anti-obesity medications (AOMs), specifically GLP-1 receptor agonists like semaglutide (2.4 mg weekly), achieve >10% body weight loss and lead to MASH resolution and fibrosis regression in patients with fibrotic MASH, offering a viable alternative to lifestyle changes alone.

Semaglutide 2.4 mg weekly is now FDA-approved for fibrotic MASH. It effectively resolves MASH and regresses fibrosis in many patients, offering a powerful tool when lifestyle changes are insufficient.

The Five-Times-Sit-to-Stand Test (FTSST) serves as a valid, safe, and affordable diagnostic tool for assessing functional mobility, identifying sarcopenia risk, and predicting falls or cognitive impairment in adults aged 50+.

Use the Five-Times-Sit-to-Stand Test as a simple, free health check. Sit in a standard chair, fold your arms, and stand up and sit down five times as fast as you can. Time yourself. Compare your time to age- and sex-specific reference values (available in this study) to gauge your functional mobility. Slower times may indicate higher risks for falls, sarcopenia, or cognitive decline, prompting a conversation with a healthcare provider.

High-dose GLP-1 receptor agonists (semaglutide 2.4 mg and tirzepatide 15 mg) produce substantial, clinically significant weight loss in adults with obesity, with tirzepatide demonstrating superior efficacy compared to other agents.

If you have obesity, high-dose GLP-1 medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective for weight loss than lifestyle changes alone. Tirzepatide showed the highest efficacy in this review. These treatments work by targeting hormonal pathways that regulate hunger and satiety, and they are most effective when combined with standard lifestyle counseling.

Tirzepatide administered once weekly produces significant weight loss (mean difference -16.32% body weight) and improves cardiometabolic markers (BMI, waist circumference, lipids, blood pressure) in patients with overweight or obesity without diabetes mellitus, though it carries a significantly elevated risk of gastrointestinal side effects.

For individuals with overweight or obesity without diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss, producing greater reductions than GLP-1 RAs like semaglutide. It also improves blood pressure, lipids, and glycemic control. However, patients must be prepared for a high likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea), which can lead to discontinuation. The overall risk of serious adverse events is not significantly higher than placebo, but the burden of GI symptoms is a key consideration for adherence.

GLP-1 receptor agonists significantly increase the likelihood of achieving weight loss compared to placebo, with tirzepatide and semaglutide demonstrating the highest relative efficacy among evaluated agents.

If you have obesity or overweight with related health issues, GLP-1 receptor agonists like semaglutide or tirzepatide are highly effective pharmacological options. They work by mimicking a hormone that reduces hunger and slows digestion. Clinical data shows they significantly increase the chance of losing weight compared to placebo, with tirzepatide and semaglutide showing the best results. These medications are FDA-approved for chronic weight management and should be used in combination with lifestyle changes.

Sustained weight loss of 5-10% or greater through negative energy balance interventions (behavioral, pharmacological, or surgical) prevents, reduces, or resolves obesity-related complications such as type 2 diabetes, hypertension, and fatty liver disease.

To significantly lower your risk of type 2 diabetes and other obesity-related diseases, you need to achieve and maintain a weight loss of at least 5-10% of your body weight. This can be done through lifestyle changes, medications, or surgery. The key is that the weight loss must be sustained over the long term, not just short-term dieting.

Greater magnitude of weight loss (e.g., >10-15%) is required to achieve remission of type 2 diabetes, whereas moderate weight loss (5-10%) is sufficient for prevention or delay.

If you want to prevent type 2 diabetes, losing 5-10% of your body weight is a great start. However, if you already have type 2 diabetes and want to achieve remission, you likely need to lose more than 10-15% of your body weight and keep it off.

Discontinuation of GLP-1 therapy leads to significant weight regain (up to two-thirds of lost weight within 1 year), highlighting the necessity of long-term lifestyle interventions and potentially long-term medication use.

Understand that GLP-1 therapy is likely a long-term treatment for obesity. If you stop the medication, you will likely regain a significant portion of your lost weight. Work with your provider to determine if you should stay on the medication long-term or transition to a maintenance strategy that includes intensive lifestyle support.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce substantial weight loss (up to 20%) by acting on CNS neural circuits, specifically the dorsal vagal complex.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often resulting in 10-20% body weight reduction. They work by acting on brain circuits that control appetite. You must take them chronically, as stopping leads to weight regain. Side effects like nausea are common but manageable.

An intensive lifestyle intervention (ILS) focused on weight loss and increased physical activity reduces the incidence of type 2 diabetes by 58% compared to placebo in high-risk adults with prediabetes, with effects sustained over 21 years.

To significantly lower your risk of developing type 2 diabetes, focus on losing 7% of your body weight and getting at least 150 minutes of moderate physical activity per week. This lifestyle approach is proven to be more effective than medication (metformin) for preventing diabetes in high-risk individuals, with benefits lasting for decades.

Metformin (850 mg twice daily) reduces the incidence of type 2 diabetes by 31% compared to placebo in high-risk adults, with greater efficacy in individuals with a BMI >= 35 kg/m2 and fasting glucose 110–125 mg/dL.

If you are at high risk for type 2 diabetes, metformin (850 mg twice daily) can reduce your risk by 31%. However, it is most effective if you have a BMI of 35 or higher or a fasting glucose between 110-125 mg/dL. Lifestyle changes remain more effective overall.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce 15–25% mean weight loss and reduce cardiovascular events by 20% and type 2 diabetes incidence by 72%.

If you have obesity or overweight with a related health condition, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Zepbound) are currently the most effective pharmacological treatments, offering 15-25% weight loss and significant cardiovascular benefits. These require weekly injections (or oral forms for some) and work best when combined with a modest caloric deficit and regular exercise. Be aware of potential gastrointestinal side effects and the need for long-term management, as stopping the medication often leads to weight regain.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves higher mean weight loss (up to 20.9%) than selective GLP-1 agonists.

Tirzepatide (Zepbound) is a once-weekly injection that targets both GIP and GLP-1 receptors, resulting in an average 20.9% weight loss over 72 weeks, which is higher than semaglutide. It is indicated for adults with obesity or overweight with comorbidities. Like other GLP-1 agonists, it requires lifestyle changes and may cause gastrointestinal side effects. Access may be limited by cost and insurance coverage.

GLP-1 receptor agonists (GLP-1 RAs) produce significant weight loss (7–24%) and HbA1c reductions (1.5–2.0%) through pleiotropic mechanisms including enhanced mitochondrial function, anti-inflammatory actions, and improved cellular quality control.

GLP-1 medications are highly effective for weight loss and blood sugar control. They work through multiple biological pathways, not just hunger suppression. Newer oral versions exist for those who prefer pills over injections. Consult a doctor to determine the right agent and dose for your specific health profile.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) reduce major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease, as well as in non-diabetic patients with obesity and cardiovascular disease.

If you have Type 2 Diabetes and heart disease, or obesity and heart disease, GLP-1 agonists like semaglutide or liraglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. This benefit exists alongside blood sugar control. Discuss with your doctor if you are a candidate, considering the cost and injection/oral delivery options.

Second-generation incretin receptor agonists (GLP-1 RAs like semaglutide and liraglutide, and dual GLP-1/GIP agonist tirzepatide) significantly reduce blood pressure and promote weight loss in obesity-related hypertension, outperforming first-generation anti-obesity drugs.

For obesity-related hypertension, second-generation incretin receptor agonists (GLP-1 RAs) like semaglutide (2.4 mg weekly) or liraglutide (3 mg daily) are the most effective pharmacological treatments for lowering blood pressure and promoting weight loss. They significantly outperform older anti-obesity drugs. These medications should be integrated with lifestyle changes (diet and exercise) and are particularly effective in non-diabetic obese patients, though they also benefit those with type 2 diabetes.

GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) significantly reduce body weight and improve metabolic health in individuals with obesity and type 2 diabetes.

If you have obesity or type 2 diabetes, GLP-1 and GIP/GLP-1 medications (like semaglutide or tirzepatide) are highly effective for weight loss and improving metabolic health. These drugs work by mimicking gut hormones to reduce appetite and improve insulin sensitivity. To get the best results and minimize side effects, start with a low dose and increase it slowly. It is also crucial to combine medication with lifestyle changes, specifically focusing on strength training and eating enough protein to protect your muscles from being lost along with fat.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) provide greater weight reduction and better metabolic control compared to GLP-1 receptor mono-agonists.

If you are not achieving sufficient weight loss with a GLP-1 medication like semaglutide, switching to a dual GIP/GLP-1 agonist like tirzepatide may offer greater benefits. Clinical trials show that tirzepatide can lead to even more significant weight loss compared to existing GLP-1 drugs. This makes it a strong option for those who need more aggressive treatment.

Tirzepatide significantly reduces apnea-hypopnea index (AHI) and resolves obstructive sleep apnea (OSA) in obese patients, with approximately 50% achieving resolution after 52 weeks of treatment.

If you have obesity and OSA, tirzepatide (10-15mg weekly) can significantly reduce your apnea severity and may even resolve OSA in half of users after one year. It is not a quick fix; it takes time to lose weight. For severe cases, it should be used alongside CPAP initially, with the goal of potentially reducing CPAP dependence as weight loss occurs. Long-term use is likely necessary to maintain benefits.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) significantly improve cardiovascular outcomes, symptoms, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, primarily through substantial weight loss and metabolic improvement.

If you have HFpEF and are obese, GLP-1 medications like semaglutide or tirzepatide are now proven to help your heart, reduce symptoms, and improve your quality of life. The key is that this is intentional weight loss, which is different from the involuntary weight loss seen in advanced heart failure. Discuss these options with your cardiologist, as they can significantly reduce your risk of hospitalization and cardiovascular death.

Dietary patterns significantly shape the gut microbiome, with fiber-rich diets increasing diversity and beneficial bacteria, while high-fat diets decrease diversity and promote pro-inflammatory species.

Prioritize fiber-rich foods (vegetables, fruits, whole grains) to support microbial diversity and beneficial bacteria. Limit high-fat, processed foods which reduce diversity and promote inflammation.

GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 agonists (e.g., tirzepatide) provide superior glycemic control and significant body weight reduction compared to standard therapies, establishing them as cornerstone treatments for type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity, GLP-1 and dual-agonist medications are now considered cornerstone treatments that offer better blood sugar control and weight loss than older therapies, especially if you have heart or kidney risks. These drugs work by mimicking gut hormones to increase insulin, slow digestion, and reduce appetite. While they can cause stomach issues, starting with a low dose and slowly increasing it helps your body adjust. Oral versions are available for some drugs, removing the need for injections for those who prefer it.